Factors predicting long-term efficacy of Hylan GF-20 viscosupplementation in knee osteoarthritis.
OBJECTIVE
To describe the long-term effects of Hylan GF-20 viscosupplementation in patients with knee osteoarthritis and to identify factors predicting efficacy.


METHODS
One hundred and fifty-five patients (80 women and 75 men; mean age, 69 years) with symptomatic knee osteoarthritis each received three intraarticular Hylan GF-20 injections. Effectiveness, safety, and satisfaction were evaluated 7-14 months later based on a physician's examination and a five-item questionnaire. Radiological data (distribution and degree of joint space loss), size of the effusion (none, moderate, large), injection route (anterior, medial to the patella, or lateral to the patellar), and side effects were recorded. Factors predicting effectiveness were looked for by univariate analysis followed by multivariable analysis with adjustments on age, body mass index, gender, and time from treatment to questionnaire administration.


RESULTS
Satisfaction was good in 78% and 58.9% of the patients according to the physician examination and questionnaire, respectively. Safety was considered excellent or good in 96.2% of the patients. Factors significantly (P < 0.05) associated with a good outcome were a moderate effusion, injection lateral to the patella, joint space loss in a single compartment, and radiological meniscal calcinosis.


CONCLUSIONS
The factors predictive of a good response to Hylan GF-20 in this study need to be confirmed, and their impact quantitated, in prospective studies.
Conrozier
Thierry
T
Rheumatology department, Centre hospitalier Lyon-Sud, 69495 Pierre-Bénite cedex, France. thierry.conrozier@chu-lyon.fr
Mathieu
Pierre
P
Schott
Anne-Marie
AM
Laurent
Isabelle
I
Hajri
Touria
T
Crozes
Pierre
P
Grand
Pierre
P
Laurent
Henri
H
Marchand
François
F
Meignan
Francis
F
Noel
Eric
E
Rozand
Yves
Y
Savoye
Jean-François
JF
Vignon
Eric
E
D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D007270:Injections, Intra-Articular; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D020370:Osteoarthritis, Knee / Q000188:drug therapy*; D017060:Patient Satisfaction; D016896:Treatment Outcome
C049816:hylan; D006820:Hyaluronic Acid